Reveal CTC heterogeneity to guide cancer therapy
QCDx LLC is a medical device company that designs, manufactures, and sells instruments, consumables and reagents for the detection of rare cells in the blood circulation.
Our mission is to reveal circulating tumor cell (CTC) heterogeneity early in cancer onset and throughout the disease trajectory to deliver precision cancer diagnosis that will guide the clinical oncologist to optimize treatment, monitor therapy, characterize metastasis and assess treatment toxicity.
Early, when cancer can be cured.
QCDx addresses the unmet need to detect and isolate intact and live, the very rare Circulating Tumor Cells (CTCs) while analyzing all nucleated cells in a blood sample.
When biopsy is not an option, these cells can offer the most valuable information on the disease biology at the time when the blood sample was collected.
They reveal molecular targets that the treating physician can use to optimize therapy.
In cancer research and the pharmaceutical industry they can enable development of novel therapeutics. Also, they may be useful for testing the effect of drugs before they are given to the patient.
QCDx technology can deliver because it offers:
ENRICHMENT-FREE rare cell detection and deep characterization.
INTACT CELL visualization in a life-sustaining 3D suspension
LIVE CELL visualization over long periods of time
SINGLE CELL isolation - intact and live
3D-CULTURE of cells and perfusion with bioactive substances
The RareScope™ Instrument for Rare Cell Detection
The RareScope instrument analyzes cells from the patient’s blood after fluorescent immunostaining of cells fixed or live.
3D optical tomography microscopy optimizes efficiency of cell detection by minimizing the effects from fluorescence of out-of-focus features.
Cells can be immunostained for up to six biomarkers and are visualized morphologically intact. Cells can be also visualized live if labeled with vital stains.
Stained cell suspensions are immobilized in a life-sustaining hydrogel within the RarePrep™ fixture that can hold more than 15 million cells.
The immobilized cell suspensions are digitized into 3D-images. These are processed to detect CTCs or other target cells, using automated Image analysis of every single cell .
The RareVivo™ specimen chamber offers a continuous 3D culture environment for the immobilized cell suspension. Flow-through media maintain cells viable for long periods while they may be visualized continually. They may contain bioactive substances, including cancer drugs to evaluate their effect on target CTCs or other target cells including the surrounding white blood cells.
Selected cells will be isolated with the RarePicker™ micro-manipulator, intact or live for down-stream molecular analyses.
Thank you for your interest in our technology. Please get in touch with us with any questions or comments.